Newman is the Chief Medical Officer of Santa Ana Bio. A veteran of the biotechnology and pharmaceutical industries, Newman brings 30 years of experience in the clinical translation and development of novel therapeutics for autoimmune and inflammatory diseases.

Newman most recently served as Chief Scientific Advisor at Protagonist Therapeutics, where he guided the development of novel peptide platforms. Prior to Protagonist, Newman spent 19 years at Janssen (Johnson & Johnson) in several senior leadership capacities, including Head of Immunology Development and R&D. During his tenure, he led a 250-member global organization and played a pivotal role as the Compound Development Team Leader for STELARA®, overseeing its journey from early development to global market leadership. His expertise spans a broad range of clinical areas, including rheumatology, gastroenterology, dermatology, and pediatric development.

Earlier in his career, Newman served as Chief of Hematology-Oncology at the Philadelphia Veterans Administration Medical Center and held a research-track faculty position focused on tumor angiogenesis.

Newman earned his M.D. from the University of Alabama at Birmingham and completed his residency in internal medicine at the Hospital of the University of Pennsylvania.